Psoriasis Uncovered Ep. 180 "Breaking Down the Immune Pathway Driving Psoriatic Disease"
Nov 15, 2022
Join Dr. Jason Hawkes, an Associate Professor of Dermatology at UC Davis, as he dissects the immune pathways at play in psoriasis and psoriatic arthritis. He highlights the crucial IL-17 and IL-23 pathways and their roles in developing targeted treatments. Discover the significance of innate immune cells and how they differ from traditional T cells. With advancements in biologic therapies and promising new treatments like bimikizumab and ducravacitinib, there's hope on the horizon for personalized care in managing this chronic condition.
AI Snips
Chapters
Transcript
Episode notes
Immune System Drives Psoriasis
- Early observations linked psoriasis improvement to immune suppression from chemotherapy and transplant medications.
- Discovery of T cells' key role led to targeted therapies blocking immune signals like TNF, IL-23, and IL-17.
TNF's Role in Psoriasis Pathway
- TNF indirectly promotes the IL-23/IL-17 pathway and synergizes with IL-17 to drive psoriasis.
- Blocking TNF reduces this feed-forward inflammation but is less direct than IL-17 or IL-23 inhibitors.
Innate Cells Influence Psoriasis
- Natural killer cells and innate lymphoid cells contribute to psoriasis by producing inflammatory signals.
- They are not regulated by IL-23, possibly explaining varied treatment responses.